Avita Therapeutics Inc (ASX: AVH) Share Price and News
Price
Movement
52 Week Range
1 Year Return
() Chart and Price Data
Avita Therapeutics Inc (ASX: AVH) Latest News
Leading broker names the ASX healthcare shares to buy in 2021
James Mickleboro | January 9, 2021 1:00pm
Why AVITA, IDP Education, Over the Wire, & Viva Energy shares are dropping lower
James Mickleboro | December 29, 2020 11:15am
These were the worst performing ASX 200 shares last week
James Mickleboro | December 19, 2020 7:49am
Recent Stock Announcements
| Date | Heading | An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security. | Time | Pages | File Size |
|---|---|---|---|---|---|
About Avita Therapeutics Inc (ASX: AVH)
Avita Therapeutics Inc (ASX: AVH) is a medical technology company that specialises in regenerative medicine. Avita’s leading product, the RECELL System, was developed to address unmet medical needs in burns. The RECELL System is used to prepare ‘spray-on skin cells’ by using a small amount of the patient’s own skin. This is a revolutionary way to treat severe burns and significantly reduces the amount of donor skin required.
RECELL was granted US Food and Drug Administration (FDA) approval in September 2018 for the treatment of acute thermal burns in patients 18 years and older. Since then, Avita has been undertaking studies to assess the use of the RECELL System in other applications. This includes the treatment of pediatric scald injuries, soft tissue reconstruction and vitiligo.
The Avita share price exploded in 2019, going from $0.081 to finish the year a phenomenal 696% higher at $0.645. With this, Avita earned itself a spot in the S&P/ASX 200 Index (ASX: XJO), as well as a place on many investors’ ASX watchlists.
Director Transactions
Data provided by Morningstar.Directors & Management
Data provided by Morningstar.Top Share Holders
Data provided by Morningstar.| Name | Shares | Capital |
|---|---|---|
| Cede & Co | 40,188,890 | 37.44% |
| HSBC Custody Nominees (Australia) Limited (I) | 7,253,182 | 6.76% |
| Citicorp Nominees Pty Limited | 7,045,639 | 6.56% |
| J P Morgan Nominees Australia Pty Limited | 6,687,839 | 6.23% |
| National Nominees Limited | 5,395,728 | 5.03% |
| Merrill Lynch (Australia) Nominees Pty Limited | 1,816,130 | 1.69% |
| Mr Michael Perry | 1,263,045 | 1.18% |
| HSBC Custody Nominees (Australia) Limited Gsco Eca | 1,252,369 | 1.17% |
| Cs Fourth Nominees Pty Limited | 1,097,835 | 1.02% |
| HSBC Custody Nominees (Australia) Limited (II) | 735,579 | 0.69% |
| Ateq Investments Pty Ltd | 590,000 | 0.55% |
| BNP Paribas Nominees Pty Ltd | 490,104 | 0.46% |
| BNP Paribas Nominees Pty Ltd (I) | 412,302 | 0.38% |
| Warbont Nominees Pty Ltd | 403,116 | 0.38% |
| Brispot Nominees Pty Ltd | 359,195 | 0.33% |
| Mr Adrian Simun Puljich | 271,765 | 0.25% |
| BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd | 244,938 | 0.23% |
| Dibbens Developments Pty Limited | 225,000 | 0.21% |
| Mr Anthony Mark Saia & Mrs Carmen Saia | 217,500 | 0.20% |
| Citicorp Nominees Pty Limited (I) | 213,979 | 0.20% |
FAQ
Will Avita Medical pay a dividend in 2020?
Avita Therapeutics shares do not currently include a dividend payment. The company has made no announcements regarding paying a dividend in 2020.
Does Avita Medical offer a DRP?
No, Avita Therapeutics does not currently offer a dividend reinvestment plan (DRP).